Pacira Pharmaceuticals buy Piper Sandler
Start price
03.07.24
/
50%
€20.40
Target price
03.07.25
€38.93
Performance (%)
-27.45%
Price
03.10.24
€14.10
Summary
This prediction is currently active. The prediction for Pacira Pharmaceuticals disappoints with a performance of -27.45%. This prediction currently runs until 03.07.25. The prediction end date can be changed by Piper_Sandler at any time. Piper_Sandler has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m |
---|---|---|
Pacira Pharmaceuticals | 10.400% | 10.400% |
iShares Core DAX® | -1.471% | 1.895% |
iShares Nasdaq 100 | -0.486% | 4.395% |
iShares Nikkei 225® | -2.115% | 2.450% |
iShares S&P 500 | 0.394% | 3.118% |
Comments by Piper_Sandler for this prediction
In the thread Pacira Pharmaceuticals diskutieren
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $42.00 price target on the stock.
Ratings data for PCRX provided by MarketBeat